Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development...
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Frontiers Media S.A.
2023-05-01
|
| Edice: | Frontiers in Medicine |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/full |